
Atopic Dermatitis (eczema) in under 12s: diagnosis and management (update) Advisory Committee Interests Register

Register last updated: 03/05/2023

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|------------------------|------------------|------------------------------|---|-------------------|----------------------|--------------------|---|
| Phil Taverner | Committee Chair | | None declared | | 09/2022 | | |
| Kaberi Alam | Committee member | | None declared | | 10/2022 | | |
| Motolani Akinbowale | Committee member | Direct financial interest | Practice Based Pharmacist, Nunhead Surgery, Nunhead | | 01/2023 | | Declare and participate – salaried employment in pharmacy services Agreed by: Guideline lead February 2023 |
| Nicola Housam | Committee member | Direct financial interest | Advanced Nurse Practitioner, United Lincolnshire Hospital Trust | 04/2012 | 12/2022 | | Declare and participate – salaried employment in the NHS Agreed by: Guideline lead January 2023 |
| Nicola Housam | Committee member | Direct financial interest | Speaker fee received from Sanofi/Regeneron speaker | 06/2022 | 12/2022 | | Declare and participate |

Atopic Dermatitis (eczema) in under 12s: diagnosis and management (update) advisory committee – interests register




| | | | on specialist clinics for atopic dermatitis patients | | | Non-specific Agreed by: Guideline lead January 2023 |
|---------------|------------------|--|--|------|---------|--|
| Sandra Lawton | Committee member | Direct financial interest | Nurse Consultant Dermatology, Rotherham NHS Foundation Trust | 2017 | 10/2022 | Declare and participate – salaried employment in the NHS Agreed by: Guideline lead |
| Sandra Lawton | Committee member | Non-financial professional and personal interest | Co-applicant - Eczema Care Online Research Study – numerous publications currently being drafted for end of study including NICE Cochrane NIHR <u>https://www.eczemacareo</u> <u>nline.org.uk/en</u> | | 10/2022 | January 2023 Declare and participate – publications were reviewed prior to each committee meeting and this was not found to represent a conflict Agreed by: Guideline lead January 2023 |
| Sandra Lawton | Committee member | Non-financial professional and personal interest | Co-applicant - BEEP (The Barrier Enhancement for Eczema Prevention) Study Research Study 5 years – final reports being written and submitted | | 10/2022 | Declare and participate - publications were reviewed prior to each committee meeting and this |



| | | | https://www.nottingham.ac .uk/research/groups/cebd/ projects/1eczema/beep- maintrial.aspx | | | | was not found to represent a conflict Agreed by: Guideline lead January 2023 |
|----------------|------------------|------------------------------|---|------|---------|------|---|
| Tess McPherson | Committee member | Direct financial interest | Consultant Dermatologist, (lead paediatric and adolescent services), Oxford University Hospitals | 2012 | 10/2022 | | Declare and participate – salaried employment in the NHS Agreed by: Guideline lead January 2023 |
| Tess McPherson | Committee member | Direct financial interest | Sanofi pharma have supported paid consultancy work (travel and honorarium) to attend panel on psychological support for patients, delivering education to health workers and development of non- promotional material. | 2018 | 10/2022 | 2022 | Declare and participate Non-specific - The company do not produce bath emollients as included within the scope. Note that Sanofi produces Dupilumab which is a systemic medication for atopic dermatitis but is outside the scope of the guideline update. |



| | | | | | | | Agreed by: Guideline lead January 2023 |
|----------------|------------------|------------------------------|---|------|---------|------|--|
| Tess McPherson | Committee member | Direct financial interest | La Rocher Posay paid (travel and honorarium) | 2018 | 10/2022 | 2022 | Declare and participate |
| | | | delivery of educational sessions to health workers | | | | Non-specific - The company do not produce bath emollients as included within the scope. Note that La Roche Posay produce topical emollient treatments some of which are designed to be used for atopic dermatitis, but these are outside the scope of the guideline update. Agreed by: Guideline lead January 2023 |
| Tess McPherson | Committee member | Direct financial interest | Private practice clinic - 1 morning session (4-5 hours) weekly, approx. 10% of practice and mirrors NHS practice. | 2016 | 10/2022 | | Declare and participate Interest is specific but accounts for only approx. 10% of clinical work and |



| | | | | | | declaration is sufficient mitigation. Agreed by: Guideline lead January 2023 |
|------------------|------------------|--|--|------|---------|--|
| Tess McPherson | Committee member | Non-financial professional and personal interest | Trustee for Charity Dipex (founder of healthtalk.org patient experiences website) | 2018 | 10/2022 | Declare and participate Non-specific Agreed by: Guideline lead January 2023 |
| Tess McPherson | Committee member | Non-financial professional and personal interest | Work with patient groups National Eczema Society and Eczema outreach society to support patients and deliver education | 2016 | 10/2022 | Declare and participate Non-specific Agreed by: Guideline lead January 2023 |
| Louise Mensah | Committee member | | None declared | | 10/2022 | |
| Jane Ravenscroft | Committee member | Direct financial interest | Consultant dermatologist with an interest in paediatric dermatology, Nottingham University Hospitals NHS Trust | 2004 | 10/2022 | Declare and participate – salaried employment in the NHS Agreed by: Guideline lead January 2023 |

NICE National Institute for Health and Care Excellence

| Jane Ravenscroft | Committee member | Non-financial professional and personal interest | Expert advisor to Nottingham eczema support group for parents and carers of children with atopic eczema | 02/2002 | 10/2022 | | Declare and participate Non-specific Agreed by: Guideline lead January 2023 |
|------------------|------------------|--|--|---------|---------|---------|--|
| Jane Ravenscroft | Committee member | Non-financial professional and personal interest | Executive committee member for British Society of Paediatric and adolescent dermatology | 11/2019 | 10/2022 | | Declare and participate Non-specific Agreed by: Guideline lead January 2023 |
| Jane Ravenscroft | Committee member | Non-financial professional and personal interest | Co-applicant on NIHR grant 'RAPID and efficient eczema trials (RAPID) | 09/2022 | 10/2022 | | Declare and participate - publications were reviewed prior to each committee meeting and this was not found to represent a conflict |
| | | | | | | | Agreed by: Guideline lead January 2023 |
| Jane Ravenscroft | Committee member | Non-financial professional and personal interest | Consultant dermatologist medical expert for NICE Guidance: ID3960 Abrocitinib, tralokinumab or upadacitinib for treating | 06/2022 | 10/2022 | 07/2022 | Declare and participate Non-specific – these technologies are not indicated for |


Atopic Dermatitis (eczema) in under 12s: diagnosis and management (update) advisory committee - interests register 6 of 10



| | | | moderate to severe atopic dermatitis | | | the treatment of under 12s Agreed by: Guideline lead January 2023 |
|------------------|------------------|--|--|---------|---------|--|
| Jane Ravenscroft | Committee member | Non-financial professional and personal interest | Co-author of research on atopic eczema which may be included as evidence in the guideline | 2000 | 10/2022 | Declare and participate - publications were reviewed prior to each committee meeting and this was not found to represent a conflict Agreed by: Guideline lead January 2023 |
| Matthew Ridd | Committee member | Direct financial interest | Associate General Practitioner (GP), Portishead Medical Group | 09/2008 | 01/2023 | Declare and participate – salaried employment in commercial organisation proving NHS services Agreed by: Guideline lead January 2023 |
| Matthew Ridd | Committee member | Non-financial professional and personal interest | In receipt of funding from NIHR for research studies | 2012 | 01/2023 | Declare and participate |

| | | and Indirect Financial interest | | | | Indirect financial interest as funding goes to member's University. Open declaration is sufficient mitigation. Agreed by: Guideline lead January 2023 |
|--------------|------------------|--|--|------|---------|---|
| Matthew Ridd | Committee member | Non-financial professional and personal interest | Co-chair of SAPC/NIHR skin and allergy specialist interest groups | 2011 | 01/2023 | Declare and participate Non-specific Agreed by: Guideline lead January 2023 |
| Matthew Ridd | Committee member | Non-financial professional and personal interest | Chief investigator/principal investigator/co-applicants on various eczema studies | 2012 | 01/2023 | Declare and participate Non-specific Agreed by: Guideline lead January 2023 |
| Matthew Ridd | Committee member | Non-financial professional and personal interest | Co-investigator on the BATHE trial (https://www.bmj.com/cont ent/361/bmj.k1332) | 2012 | 01/2023 | Declare and participate While this is a Direct, Specific interest, the benefit of the member's expertise in this |

| | | | | | | topic outweighs a risk of bias. However, to mitigate that risk, the member was excluded from the initial drafting of recommendations at the Development meeting and the redrafting of recommendations at the post- consultation meeting and then gave a view on the committee's drafts. Agreed by: Guideline lead January 2023 |
|------------------------|------------------|------------------------------|---|---------|---------|---|
| Jothsana Srinivasan | Committee member | Direct financial interest | Consultant General Paediatrician with expertise in Paediatric Dermatology, Nottingham University hospitals NHS Trust | 03/2016 | 10/2022 | Declare and participate – salaried employment in the NHS Agreed by: Guideline lead January 2023 |
| Marco Yeung | Committee member | Direct financial interest | Medicine Optimisation Pharmacist, NHS Bath and | | 12/2022 | Declare and participate – |



| North East Somerset, Swindon and Wiltshire Integrated Care Board | salaried employment in the NHS |
|--|---|
| | Agreed by: Guideline lead February 2023 |

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.